NUMA1 and urothelial carcinoma: Numerous diagnostic tests were developed and validated by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) in recent years, such as the bladder tumor antigen (BTA) [12], nuclear matrix protein 22 (NMP22) [13], ImmunoCyt/uCyt+, and UroVysion as urinary biomarkers for the detection and surveillance of urothelial carcinomas, as reported by Soria F et al. [14].